Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan.
Irvine, California-based Allergan Inc. has rejected several acquisition bids from Valeant, the latest amounting to about $53 billion. Its executives have said Valeant would slash research and development funding too much if it took over. They’ve also said the offers undervalue their company.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.